Age-related Macular Degeneration (ARMD)
7
1
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
5 treatments under study, led by Faricimab
Research Leaders
7 sponsors active, led by Kim's Eye Hospital
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
1 terminated out of 7 trials
66.7%
-19.9% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (7)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
Can the Risk for AMD be Modulated?
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities
PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Research Network
Common Treatments
- Faricimab1
- Ranibizumab1
- Ilumen Amd1
- Blood Draw1
- Aflibercept1
Active Sponsors
- Kim's Eye Hospital2
- Association for Innovation and Biomedical Research on Light and Image1
- University of Missouri-Columbia1
- Beijing Hospital1
- i-Lumen Scientific AUS PTY LTD1
Top Investigators
Rush University Medical Center
Pepose Vision Institute
University of Missouri-Columbia
Novartis - Including Sites in Germany
i-Lumen Scientific, Inc.
Related Conditions
- Choroidal Neovascularization1
- Intermediate Amd1
- Agerelated Macular Degeneration1
- Geographic Atrophy Secondary To Agerelated Macular Degeneration1
- Antivascular Endothelial Growth Factor1